Why your SaaS trial signups climb while paid revenue stays flat
A B2B SaaS company's free trial signups can climb for two quarters while paid revenue stays flat. The rising number is often the cause, not wasted demand. The trial-to-paid gap lives in three places, each needing a different fix.
By Stacey Tallitsch | June 10, 2026
Your free trial signups have been climbing for two quarters. The chart your marketing lead screenshots every Monday goes up and to the right. New paid revenue, over the same two quarters, has not moved.
Sales says the trials are tire-kickers. Marketing says signups are up 40% and points back at sales. One vendor is pitching you a better onboarding tool and another is pitching you a product-led growth consultant, and you cannot tell which of them, if either, is describing your actual problem. You run a B2B software company somewhere under $10M in annual recurring revenue, and the one number everyone celebrates is the number hiding what is actually wrong.
The signup line measures the door, not the demand
A signup count tells you how many people walked through the door. It does not tell you who they were or why they came. When that number rises while paid revenue holds flat, the instinct is to treat the gap as waste: good demand that sales or onboarding is failing to capture. Sometimes that is true. Often the rising number is not unconverted demand at all. It is the cause.
Here is the mechanism. Marketing has a volume target, so marketing widens the door. They broaden the keywords, list you on a software deal site, launch a free tool, run a campaign that promises something the product almost does. Signups climb. But the new signups are a different population than the ones who used to convert. Your conversion rate did not fall on your old traffic. You diluted your old traffic with people who were never going to buy, and the blended signup number averages the two groups into a single line that looks like growth.
This is why a signup chart and a revenue chart can point in opposite directions for two full quarters without either team lying. They are measuring different physics, the same way a marketing dashboard can show every metric climbing while the P&L stays flat. The dashboard is honest. It is just answering a different question than the one you need answered.
The data on this is blunt. In an analysis of 200 B2B software products, most of them, like you, between $1M and $10M ARR, the median free-to-paid conversion rate was 8%, but almost no company actually sits at 8%. The distribution is bimodal. Products are either in the low single digits or above 15%, with a 10x gap between the top fifth and the bottom fifth. A blended signup number cannot tell you which side of that gap a given cohort lands on. That is the whole problem. The number you are proud of is the number that erases the distinction you need.
So stop reading the signup line as a score. Read it as a question with three possible answers.
Three places the trial-to-paid gap actually lives
The gap between rising trials and flat revenue is not one problem. It is three, and they look identical from the signup dashboard. Each one requires a different fix, and the fix for one makes the other two worse.
The wrong people are signing up
The first cause lives upstream, in acquisition. The trials that convert and the trials that do not are not random. They come from different sources, different campaigns, different promises. When marketing optimizes for raw volume, it reaches for the cheapest signups available, and the cheapest signups are almost always the lowest-intent ones. You added 40% more trials and 0% more buyers because the 40% was the wrong 40%.
You can see this without a new tool. Pull your last two quarters of trials and segment them by source. If trials from your old, narrow channels still convert at the old rate, and the new volume converts at a fraction of it, you have a fit problem, not a product problem. More leads will not fix it. More leads is what caused it. This is also where the standing sales-versus-marketing fight actually gets settled, because the argument is never really about lead quality in the abstract. It is about which cohort each team is looking at.
The right people sign up and never reach the moment worth paying for
The second cause lives inside the trial. The right user signs up, intends to evaluate you, and never reaches the point where the product becomes obviously worth money. They do not import their data. They do not connect the one integration that makes the tool theirs. They poke at an empty dashboard, get pulled into their actual job, and the 14-day clock runs out on a product they never really used.
This is the cause an onboarding tool can genuinely help, and it is invisible on a signup report. The signup fired. Everything that determined conversion happened after it and got measured by nothing. The question to answer is the one the ChartMogul researchers put at the center of the same report: at what point does a user actually hit the moment the product clicks, immediately or only after real setup work? If your aha moment sits behind 45 minutes of configuration and your trial assumes it happens in the first session, your funnel is leaking in a place no acquisition spend can reach.
The right people activate and have no reason to buy now
The third cause lives in pricing and packaging. The user signs up, reaches the aha moment, gets the value, and then keeps getting it, for free, with no event that forces a decision. A free tier generous enough to run a real workload on is not a trial. It is a destination. Conversion stays flat not because the product failed but because nothing in the structure ever asks the user to pay.
The mirror image is a trial so frictionless it selects for people with no intent. The same research found that free trials requiring a credit card convert at roughly 30%, more than five times the rate of trials that do not, not because the card is magic, but because requiring it filters out everyone who was never serious. Your frictionless signup flow may be manufacturing the exact tire-kickers your sales team complains about. That is a packaging decision wearing a marketing costume.
What to do before you buy either fix
Notice what just happened. The onboarding tool one vendor is selling you only addresses the second cause. The growth consultant only reframes the third. Neither touches the first, and if your real problem is cohort dilution, both purchases burn a quarter and a budget while the signup line keeps climbing and the revenue line keeps not.
So do the cheap thing first, today, before you sign anything. Export your last 90 days of trials. Tag each one by acquisition source and by whether it ever reached your activation event, the single action that best predicts a paid conversion. You will land in one of three places. If the new volume comes from new sources and never activates, you have a fit problem and you should narrow the door, not widen it. If trials activate and still do not convert, you have a packaging problem and the lever is your pricing, not your funnel. If they sign up and never activate at all, you have a real onboarding problem and that vendor is, for once, selling the right fix.
One afternoon of segmentation tells you which of three conversations to have. Buying the fix before you have run it is how a flat quarter becomes a flat year. If you are early enough that you are also weighing whether to bring in senior marketing help to sort this out, run the diagnosis first anyway. The answer changes whether you need a Fractional CMO at all, and you should never hire to diagnose a problem you can read yourself in an afternoon.
— Stacey Tallitsch, Stronghold CMO
About the Author
Stacey Tallitsch is the President of Stronghold CMO, a Fractional AI CMO service operating under Talisman Capital, Inc. He is a 30-year tech veteran and the author of 21 books on systems thinking, operator-grade decision-making, and personal sovereignty, with more than 30,000 students across his Udemy course catalog.